Pasithea Therapeutics Corp. KTTA 深 沪
已收盘 12-19 16:00:00 美东时间
1.16
+0.060
+5.45%
华盛通- 最 高1.16
- 今 开1.09
- 成交量 65.56万股
- 最 低 1.0187
- 昨 收 1.10
- 总市值 863.46万
- 52周最高 3.85
- 市盈率 静 --
- 换手率 8.81%
- 52周最低 0.281
- 委 比 61.85%
- 总股本 744.36万
- 历史最高 170.00
- 量 比 0.92
- 振 幅 12.85%
- 历史最低 0.281
- 每 手 1
- 风险率 0.63%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pasithea Therapeutics Regains Nasdaq Compliance
Pasithea Therapeutics Corp ( ($KTTA) ) has shared an announcement. Pasithea The...
12-15 21:55
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
12-09 10:32
HC Wainwright & Co. Initiates Coverage On Pasithea Therapeutics with Buy Rating, Announces Price Target of $3
HC Wainwright & Co. analyst Sara Nik initiates coverage on Pasithea Therapeutics (NASDAQ:KTTA) with a Buy rating and announces Price Target of $3.
12-08 20:44
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers GT Biopharma (NASDAQ:GTBP) shares moved upwards by 6.6% to $0.65 durin...
12-06 05:05
Pasithea Therapeutics Announces Pricing Of Public Offering Of 80M Shares At Offering Price Of $0.75/Shr Of Common Stock
Extends cash runway through at least the first half of 2028Led by Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron Capital
11-28 22:25
Why Heartbeam Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket
Shares of Heartbeam Inc (NASDAQ:BEAT) rose sharply in pre-market trading after ...
11-28 17:49
Pasithea Therapeutics Announces Phase 1 Data From Its Ongoing First-In-Human Trial Evaluating PAS-004; Partial Response Observed In A MEK-Rechallenge 3rd-line Melanoma Patient With Braf V600e Mutation Who Remains On Trial For More Than 11 Months; PAS-004 Has Been Well-Tolerated With All Treatment
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of neurofibromatosis
11-21 05:06
Pasithea Therapeutics Q3 EPS $(0.41) Up From $(2.87) YoY
Pasithea Therapeutics (NASDAQ:KTTA) reported quarterly losses of $(0.41) per share. This is a 85.71 percent increase over losses of $(2.87) per share from the same period last year.
11-14 06:34
Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
Pasithea Therapeutics Corp. announced the activation of a new U.S. clinical trial site at the University of Alabama at Birmingham (UAB) for its Phase 1/1b study evaluating PAS-004 in adult patients with neurofibromatosis type 1 (NF1). The UAB site adds to the global clinical trial network assessing the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PAS-004. Concurrently, Pasithea is the Platinum Sponsor of the 2025 NF C...
11-04 12:03
Kratos Forms Strategic Partnership with Korean Industry Leader to Advance Manned-Unmanned Teaming
Kratos Defense & Security Solutions has partnered with Korea Aerospace Industries (KAI) to advance Manned-Unmanned Teaming (MUM-T) technologies. The collaboration combines Kratos' expertise in unmanned aerial systems with KAI's aerospace technologies to develop affordable, interoperable solutions for enhanced joint force readiness and operational flexibility. The partnership focuses on joint research, system integration, and scalable MUM-T applic...
10-27 13:00
